

英文原版

# 癌症基因治疗学

# Gene Therapy of Cancer

**Second Edition**

*Edited by*

**Edmund C. Lattime  
Stanton L. Gerson**



人民卫生出版社



Health Science Asia,  
Elsevier Science

S E C O N D   E D I T I O N

# GENE THERAPY OF CANCER

Translational Approaches from Preclinical  
Studies to Clinical Implementation

Edited by

**EDMUND C. LATTIME, PhD**

*Departments of Surgery and Molecular Genetics & Microbiology  
The Cancer Institute of New Jersey  
UMDNJ–Robert Wood Johnson Medical School  
Piscataway, New Jersey*

**STANTON L. GERSON, MD**

*Division of Hematology/Oncology  
Department of Medicine and Ireland Cancer Center at Case Western Reserve University  
and University Hospitals of Cleveland  
Cleveland, Ohio*

人民卫生出版社

Health Science Asia, Elsevier Science

人民卫生出版社

Health Science Asia, Elsevier Science

Original English Language Edition

Copyright © 2002, 1999 by ACADEMIC PRESS

All Rights Reserved.

Authorized English Reprints

Copyright © 2002 by Health Science Asia, Elsevier Science

### 图书在版编目(CIP)数据

癌症基因治疗学 / (美) 拉蒂姆著. —影印本. —北京:  
人民卫生出版社, 2002

ISBN 7-117-05105-1

I . 癌… II . 拉… III . 癌—基因治疗—英文  
IV . R730.59

中国版本图书馆 CIP 数据核字 (2002) 第 063522 号

图字: 01-2002-1959

### 癌症基因治疗学 (英文版)

原 著: EDMUNDC. LATTIME, PhD

出版发行: 人民卫生出版社(中继线 67616688)

地 址: (100078)北京市丰台区方庄芳群园3区3号楼

网 址: <http://www.pmph.com>

E-mail: [pmph@pmph.com](mailto:pmph@pmph.com)

印 刷: 北京市安泰印刷厂

经 销: 新华书店

开 本: 889×1194 1/16 印张: 34.75 插页: 4

字 数: 1364 千字

版 次: 2002年10月第1版 2002年10月第1版第1次印刷

标准书号: ISBN 7-117-05105-1/R · 5106

定 价: 119.00元

著作权所有, 请勿擅自用本书制作各类出版物, 违者必究

(凡属质量问题请与本社发行部联系退换)

## Preface

---

The second edition of *Gene Therapy of Cancer* comes at a pivotal transition point in the development of this exciting technology. Much has occurred in the past 4 years to catapult preclinical and basic scientific concepts into therapeutic trials. In addition, while the outcome of the initial phase of clinical trials using gene therapy to target cancers has not yielded the amazing results initially hoped for, as with every new therapeutic venture in medicine, initial results provide the fodder for critical experiments, new targets, and new questions that propel the field forward.

We have reorganized the presentations in the second edition to reflect the continued new emerging strategies that will ultimately lead to the success of this therapeutic approach and have added introductory chapters to a number of the sections with the goal of setting the contributions in their proper basic scientific context.

Immune therapeutics takes on added emphasis given some of the recent breakthroughs in vaccine development and targeted delivery. Oncolytic virus therapeutics have also emerged in a very promising light with initial positive results observed in head and neck cancer leading to a number of preclinical advances. Therapies directed towards oncogenes, be it by expression of normal oncogenes, use of ribozymes and antisense therapeutics, and the use of E1A continue to be promising in preclinical and early clinical models. Hematopoietic stem cells are being used in gene therapy both in the antisense setting, for instance use of BCR/ABL antisense to block CML stem cell proliferation, and in genetically modified stem cells as immunotherapies. In addition, bone marrow protection by introduction of a drug-resistant gene into hematopoietic stem cells is entering its next phase

of clinical trials and appears to have accomplished its goal of achieving stem cell protection in both preclinical and clinical settings.

Gene delivery remains an important aspect of gene therapy of cancer and a number of chapters focus on gene delivery systems using both viral and nonviral approaches.

The reader will find this to be a comprehensive assessment of the current state of gene therapy of cancer offering state of the art research, a review of basic mechanisms and approaches, and a compilation of current clinical trial efforts.

We have not encumbered this text with a number of the current controversies in gene therapy but would note the importance of these issues in the field. Conflict of interest remains an active area of discussion at every major cancer center in the country and has been the recent focus of the American Society of Gene Therapy. The careful monitoring of patients undergoing clinical trials in gene therapy will remain a priority for all clinical trialists in this field. Linking preclinical models to clinical endpoints is an important aspect of this focus and will enable intermediate assessments to define whether the gene therapy effect has been achieved prior to relying on clinical cancer response and will help drive both Phase I and Phase II clinical trial design.

The next 5 years will be explosive in the next generation of preclinical and clinical developments of gene therapy of cancer. We hope this second edition will provide an important reference for investigators and observers alike in this exciting field.

Edmund C. Lattime, PhD  
Stanton L. Gerson, MD



## Contributors

---

*Numbers in parentheses indicate the pages on which the authors' contribution begin.*

- Rafat Abonour** (355) Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202
- Scott I. Abrams** (145) Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
- Laura K. Aguilar** (513) Harvard Gene Therapy Initiative, Harvard Medical School, Boston, Massachusetts 02115
- Estuardo Aguilar-Cordova** (513) Department of Radiology, Baylor College of Medicine, Houston, Texas 77030 and Harvard Gene Therapy Initiative, Harvard Medical School, Boston, Massachusetts 02115
- Steven M. Albelda** (493) Thoracic Oncology Research Laboratory, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104
- Mark R. Albertini** (225) The University of Wisconsin, Comprehensive Cancer Center, Madison, Wisconsin 53792
- Gustavo Ayala** (513) Department of Pathology, Baylor College of Medicine, Houston, Texas 77030
- Jacques Banchereau** (167) Baylor Institute for Immunology Research, Dallas, Texas 75204
- Christopher Baum** (3) Medizinische Hochschule, Abt. Haematologie, 30625 Hannover, Germany
- Christian M. Becker** (421) Department of Surgery, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
- Carmela Beger** (95) Department of Medicine, University of San Diego, La Jolla, California 92093
- Joseph R. Bertino** (365) Department of Medicine, Division of Hematologic Oncology and Lymphoma, and Programs of Molecular Pharmacology and Therapeutics, Memorial-Sloan Kettering Cancer Center, New York, New York 10021
- Patrick Blanco** (167) Baylor Institute for Immunology Research, Dallas, Texas 75204
- Tulin Budak-Alpdogan** (365) Department of Medicine, Programs of Molecular Pharmacology and Therapeutics, Memorial-Sloan Kettering Cancer Center, New York, New York 10021
- E. Brian Butler** (513) Department of Radiology, Baylor College of Medicine, Houston, Texas 77030
- Lisa H. Butterfield** (179) Division of Surgical Oncology, UCLA Medical Center, University of California, Los Angeles, California 90095
- Alfred E. Chang** (241) Department of Surgery, Division of Surgical Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109
- Saswati Chatterjee** (53) Division of Virology, City of Hope National Medical Center, Duarte, California 91010
- K. V. Chin** (393) Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Virginia K. Clements** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- Mark J. Cooper** (31) Copernicus Therapeutics, Inc., Cleveland, Ohio 44106

- Kenneth Cornetta** (355) Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202
- James M. Croop** (355) Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202
- Samudra Dissanayake** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- Stephen L. Eck** (505) HUP-Department of Neurosurgery, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19004
- James S. Economou** (179) Division of Surgical Oncology, and Department of Immunology, Microbiology, and Molecular Genetics, UCLA Medical Center, University of California, Los Angeles, California 90095
- Laurence C. Eisenlohr** (207) Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- Wafik S. El-Deiry** (273, 279, 299) Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of Medicine and Genetics, Cancer Center and The Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- Filip A. Farnebo** (421) Departments of Surgery and Genetics, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
- Andrew L. Feldman** (405) Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892
- Judah Folkman** (421) Department of Surgery, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
- Stanton L. Gerson** (341) Division of Hematology/Oncology, Department of Medicine and Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106
- Mileka Gilbert** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- Leonard G. Gomella** (207) Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- David H. Gorski** (435) The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901
- William N. Hait** (393) Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Mien-Chie Hung** (465) Departments of Molecular and Cellular Oncology and Surgical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston, Texas 77030
- Kevin D. Judy** (505) HUP-Department of Neurosurgery, The University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19004
- Dov Kadmon** (513) Department of Urology, Baylor College of Medicine, Houston, Texas 77030
- Thomas Kearney** (393) Department of Surgery, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Edsel U. Kim** (257) Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan 48109
- David M. King** (225) The University of Wisconsin, Comprehensive Cancer Center, Madison, Wisconsin 53792
- David Kirn** (449) Imperial Cancer Research Fund, Program for Viral and Genetic Therapy of Cancer, Imperial College School of Medicine, Hammersmith Hospital, London W11 0HS, United Kingdom
- Omer N. Koç** (341) Division of Hematology/Oncology, Department of Medicine and Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106
- Martin Krüger** (95) Department of Medicine, University of San Diego, La Jolla, California 92093
- Calvin J. Kuo** (421) Departments of Surgery and Genetics, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
- C. Lampert** (81) Department of Hematology and Medical Oncology, St. Peter's University Hospital, New Brunswick, New Jersey 08901
- Edmund C. Lattime** (207, 393) Departments of Surgery and Molecular Genetics & Microbiology, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Irina V. Lebedeva** (315) Department of Medicine and Pharmacology, Columbia University, College of Physicians and Surgeons, New York, New York 10032
- Steven K. Libutti** (405) Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892

- H. Kim Lyerly** (199) Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
- Michael J. Mastrangelo** (207) Division of Medical Oncology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
- Helena J. Mauceri** (435) Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637
- A. M. McCall** (81) Fox Chase Cancer Center, Philadelphia, Pennsylvania 91010
- Kevin T. McDonagh** (241) Department of Internal Medicine, Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109
- R. Scott McIvor** (383) Gene Therapy Program, Institute of Human Genetics, Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota 55455
- Raymond D. Meng** (273, 279, 299) Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Departments of Medicine and Genetics, Cancer Center and The Institute for Human Gene Therapy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
- Brian Miles** (513) Department of Urology, Baylor College of Medicine, Houston, Texas 77030
- Frederick L. Moolten** (481) Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts 01730 and Boston University School of Medicine, Boston, Massachusetts 02118
- Michael A. Morse** (199) Department of Medicine, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710
- Paula J. Mroz** (481) Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts 01730
- James J. Mulé** (257) Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109
- Smita K. Nair** (199) Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
- Owen A. O'Connor** (365) Department of Medicine, Division of Hematologic Oncology and Lymphoma, and Developmental Chemotherapy Services, Memorial-Sloan Kettering Cancer Center, New York, New York 10021
- Wolfram Ostertag** (3) Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg, 20251 Hamburg, Germany
- Suzanne Ostrand-Rosenberg** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- A. Karolina Palucka** (167) Baylor Institute for Immunology Research, Dallas, Texas 75204
- Beth A. Pulaski** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- Ling Qi** (127) Department of Biological Sciences, University of Maryland, Baltimore, Maryland 21250
- Alexander L. Rakhmievich** (225) The University of Wisconsin, Comprehensive Cancer Center, Madison, Wisconsin 53792
- Jane S. Reese** (341) Division of Hematology/Oncology, Department of Medicine and Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106
- Michael Reiss** (393) Department of Medicine, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Antoni Ribas** (179) Division of Surgical Oncology, and Division of Hematology/Oncology, UCLA Medical Center, University of California, Los Angeles, California 90095
- Isabelle Rivière** (109) Laboratory of Gene Transfer and Gene Expression, Department of Medicine and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- Justin C. Roth** (341) Division of Hematology/Oncology, Department of Medicine and Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106
- Michel Sadelain** (109) Laboratory of Gene Transfer and Gene Expression, Department of Medicine and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- Ruping Shao** (465) Department of Molecular and Cellular Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston, Texas 77030
- C. A. Stein** (315) Department of Medicine and Pharmacology, Columbia University, College of Physicians and Surgeons, New York, New York 10032

- Daniel H. Stermán** (493) Thoracic Oncology Research Laboratory, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104
- Carol Stocking** (3) Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg, 20251 Hamburg, Germany
- Bin S. Teh** (513) Department of Radiology, Baylor College of Medicine, Houston, Texas 77030
- Timothy C. Thompson** (513) Department of Urology, Baylor College of Medicine, Houston, Texas 77030
- Deborah Toppmeyer** (393) Department of Medicine, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey 08901
- Catherine M. Verfaillie** (331) Stem Cell Institute, Cancer Center, and Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455
- Maria T. Vlachaki** (513) Department of Radiology and Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas 77030
- Dorothee von Laer** (3) Chemotherapeutisches Forschungsinstitut, Georg-Speyer-Haus, 60596 Frankfurt, Germany
- Ralph R. Weichselbaum** (435) Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637
- L. M. Weiner** (81) Fox Chase Cancer Center, Philadelphia, Pennsylvania 91010
- Thomas Wheeler** (513) Department of Pathology, Baylor College of Medicine, Houston, Texas 77030
- Lee G. Wilke** (257) Department of Surgery, University of Michigan, Ann Arbor, Michigan 48109
- K. K. Wong, Jr.** (53) Division of Hematology and Bone Marrow Transplantation, and Division of Virology, City of Hope National Medical Center, Duarte, California 91010
- Flossie Wong-Staal** (95) Department of Medicine, University of San Diego, La Jolla, California 92093
- Duen-Hwa Yan** (465) Departments of Molecular and Cellular Oncology and Surgical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston, Texas 77030
- Steven P. Zielske** (341) Division of Hematology/Oncology, Department of Medicine and Ireland Cancer Center at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106
- Robert CH Zhao** (331) Stem Cell Institute, Cancer Center, and Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455



# Preface

---

The second edition of *Gene Therapy of Cancer* comes at a pivotal transition point in the development of this exciting technology. Much has occurred in the past 4 years to catapult preclinical and basic scientific concepts into therapeutic trials. In addition, while the outcome of the initial phase of clinical trials using gene therapy to target cancers has not yielded the amazing results initially hoped for, as with every new therapeutic venture in medicine, initial results provide the fodder for critical experiments, new targets, and new questions that propel the field forward.

We have reorganized the presentations in the second edition to reflect the continued new emerging strategies that will ultimately lead to the success of this therapeutic approach and have added introductory chapters to a number of the sections with the goal of setting the contributions in their proper basic scientific context.

Immune therapeutics takes on added emphasis given some of the recent breakthroughs in vaccine development and targeted delivery. Oncolytic virus therapeutics have also emerged in a very promising light with initial positive results observed in head and neck cancer leading to a number of preclinical advances. Therapies directed towards oncogenes, be it by expression of normal oncogenes, use of ribozymes and antisense therapeutics, and the use of E1A continue to be promising in preclinical and early clinical models. Hematopoietic stem cells are being used in gene therapy both in the antisense setting, for instance use of BCR/ABL antisense to block CML stem cell proliferation, and in genetically modified stem cells as immunotherapies. In addition, bone marrow protection by introduction of a drug-resistant gene into hematopoietic stem cells is entering its next phase

of clinical trials and appears to have accomplished its goal of achieving stem cell protection in both preclinical and clinical settings.

Gene delivery remains an important aspect of gene therapy of cancer and a number of chapters focus on gene delivery systems using both viral and nonviral approaches.

The reader will find this to be a comprehensive assessment of the current state of gene therapy of cancer offering state of the art research, a review of basic mechanisms and approaches, and a compilation of current clinical trial efforts.

We have not encumbered this text with a number of the current controversies in gene therapy but would note the importance of these issues in the field. Conflict of interest remains an active area of discussion at every major cancer center in the country and has been the recent focus of the American Society of Gene Therapy. The careful monitoring of patients undergoing clinical trials in gene therapy will remain a priority for all clinical trialists in this field. Linking preclinical models to clinical endpoints is an important aspect of this focus and will enable intermediate assessments to define whether the gene therapy effect has been achieved prior to relying on clinical cancer response and will help drive both Phase I and Phase II clinical trial design.

The next 5 years will be explosive in the next generation of preclinical and clinical developments of gene therapy of cancer. We hope this second edition will provide an important reference for investigators and observers alike in this exciting field.

Edmund C. Lattime, PhD  
Stanton L. Gerson, MD

# Contents

---

Contributors xv  
Preface xix

---

## PART

### I

## VECTORS FOR GENE THERAPY OF CANCER

### 1. Retroviral Vector Design for Cancer Gene Therapy

CHRISTOPHER BAUM, WOLFRAM OSTERTAG,  
CAROL STOCKING, AND DOROTHEE VON LAER

- I. Introduction 3
- II. Applications for Retroviral Vectors in Oncology 4
- III. Biology of Retroviruses 6
- IV. Principles of Retroviral Vector Systems 9
- V. Advances in Retroviral Vector Tailoring 11
- VI. Outlook 22
- References 23

### 2. Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy

MARK J. COOPER

- I. Introduction 31
- II. Advantages and Disadvantages of Infectious,  
Viral-Based Vectors for Human Gene Therapy 31
- III. Rationale for Considering Noninfectious,  
Plasmid-Based Expression Systems 33
- IV. Gene Transfer Technologies for Plasmid-Based Vectors:

Preclinical Models and Clinical Cancer Gene Therapy  
Trials 33

- V. Plasmid Expression Vectors 37
- VI. Future Directions 43
- References 45

### 3. Parvovirus Vectors for the Gene Therapy of Cancer

K. K. WONG, JR. AND SASWATI CHATTERJEE

- I. Introduction 53
- II. Biology of Parvoviridae and Vector Development 54
- III. Applications of Recombinant Parvovirus Vectors to  
Cancer Gene Therapy 61
- IV. Perspectives, Problems, and Future Considerations 71
- References 71

### 4. Antibody-Targeted Gene Therapy

C. LAMPERT, A. M. MCCALL, AND L. M. WEINER

- I. Introduction 81
- II. Background: Monoclonal Antibodies and  
Cancer Therapy 81
- III. Recent Advances: Monoclonal-Antibody-Mediated  
Targeting and Cancer Gene Therapy 84
- IV. Future Directions 91
- References 92

### 5. Ribozymes in Cancer Gene Therapy

CARMELA BEGER, MARTIN KRÜGER,  
AND FLOSSIE WONG-STAAL

- I. Introduction 95
- II. Ribozyme Structures and Functions 96

- III. Cancer Disease Models for Ribozyme Application 98  
 IV. Challenges and Future Directions 102  
 References 103

## 6. The Advent of Lentiviral Vectors: Prospects for Cancer Therapy

MICHEL SADELAIN AND ISABELLE RIVIÈRE

- I. Introduction 109  
 II. Structure and Function of Lentiviruses 110  
 III. Features that Distinguish Lentiviral from Oncoretroviral Vectors 111  
 IV. Manufacture of Lentiviral Vectors 113  
 V. Possible Applications of Lentiviral Vectors in Cancer Therapy 117  
 VI. Conclusions 119  
 References 120

### PART

## II

## IMMUNE TARGETED GENE THERAPY

### 7. Immunologic Targets for the Gene Therapy of Cancer

SUZANNE OSTRAND-ROSENBERG, VIRGINIA K. CLEMENTS,  
 SAMUDRA DISSANAYAKE, MILEKA GILBERT,  
 BETH A. PULASKI, AND LING QI

- I. Introduction 128  
 II. Cellular (T-Lymphocyte-Mediated) Versus Humoral (Antibody-Mediated) Immune Responses to Tumor Cells 128  
 III. Response of CD4<sup>+</sup> and CD8<sup>+</sup> T Lymphocytes to Tumor Antigens Presented in the Context of Molecules Encoded by the Major Histocompatibility Complex 129  
 IV. Response of Tumor-Bearing Individuals to Tumor Antigens 132  
 V. Tumor-Associated Peptides as Candidate Targets for Tumor-Specific T Lymphocytes 133  
 VI. Immunotherapeutic Strategies for the Treatment of Cancer 135  
 VII. Conclusions 138  
 References 138

### PART

## Ila

## VACCINE STRATEGIES

### 8. Development of Epitope-Specific Immunotherapies for Human Malignancies and Premalignant Lesions Expressing Mutated *ras* Genes

SCOTT I. ABRAMS

- I. Introduction 145  
 II. Cellular Immune Response and Antigen Recognition 146  
 III. Pathways of Antigen Processing, Presentation, and Epitope Expression 146  
 IV. T-Lymphocyte Subsets 147  
 V. *ras* Oncogenes in Neoplastic Development 147  
 VI. Cellular Immune Responses Induced by *ras* Oncogene Peptides 149  
 VII. Identification of Mutant *ras* CD4<sup>+</sup> and CD8<sup>+</sup> T-Cell Epitopes Reflecting Codon 12 Mutations 149  
 VIII. Anti-*ras* Immune System Interactions: Implications for Tumor Immunity and Tumor Escape 156  
 IX. Paradigm for Anti-*ras* Immune System Interactions in Cancer Immunotherapy 158  
 X. Future Directions 159  
 References 160

### PART

## Iib

## DENDRITIC CELL-BASED GENE THERAPY

### 9. Introduction to Dendritic Cells

PATRICK BLANCO, A. KAROLINA PALUCKA,  
 AND JACQUES BANCHEREAU

- I. Introduction 167  
 II. Features of Dendritic Cells 167  
 III. Dendritic Cell Subsets 169  
 IV. Functional Heterogeneity of Dendritic Cell Subsets 171  
 V. Dendritic Cells in Tumor Immunology 172  
 VI. Dendritic Cells and Gene Therapy 173  
 VII. Conclusions 174  
 References 174

## 10. DNA and Dendritic Cell-Based Genetic Immunization Against Cancer

LISA H. BUTTERFIELD, ANTONI RIBAS,  
AND JAMES S. ECONOMOU

- I. Introduction 179
- II. Background 179
- III. Recent Advances: Methods of Genetic Immunization 183
- IV. Preclinical Development and Translation to the Clinic 190
- V. Proposed and Current Clinical Trials 190
- VI. Future Directions 191
- References 191

## 11. RNA-Transfected Dendritic Cells as Immunogens

MICHAEL A. MORSE, SMITA K. NAIR, AND H. KIM LYERLY

- I. Introduction 199
- II. Advantages of Loading Dendritic Cells with Genetic Material 199
- III. Viral Versus Nonviral Methods of Gene Transfer 200
- IV. RNA Versus DNA Loading of Dendritic Cells 200
- V. RNA Loading of Dendritic Cells 201
- VI. Amplification of RNA Used to Load Dendritic Cells 201
- VII. Uses of RNA-Loaded Dendritic Cells 201
- VIII. Future Directions 202
- References 202

### PART

## IIC

## CYTOKINES AND CO-FACTORS

### 12. *In Situ* Immune Modulation Using Recombinant Vaccinia Virus Vectors: Preclinical Studies to Clinical Implementation

EDMUND C. LATTIME, LAURENCE C. EISENLOHR, LEONARD G. GOMELLA, AND MICHAEL J. MASTRANGELO

- I. Introduction 207
- II. Generation of Cell-Mediated Immune Responses 208
- III. Cytokine Gene Transfer Studies in Antitumor Immunity 210
- IV. *In Situ* Cytokine Gene Transfer to Enhance Antitumor Immunity 210

- V. Future Directions 215
- VI. Conclusions 218
- References 219

## 13. The Use of Particle-Mediated Gene Transfer for Immunotherapy of Cancer

MARK R. ALBERTINI, DAVID M. KING, AND  
ALEXANDER L. RAKHMILEVICH

- I. Introduction 225
- II. Background 225
- III. Recent Advances 228
- IV. Issues Regarding Evaluation in Clinical Trials 234
- V. Recent Clinical Trials 234
- VI. Potential Novel Uses and Future Directions 235
- References 235

### PART

## IId

## GENETICALLY MODIFIED EFFECTOR CELLS FOR IMMUNE-BASED IMMUNOTHERAPY

### 14. Applications of Gene Transfer in the Adoptive Immunotherapy of Cancer

KEVIN T. McDONAGH AND ALFRED E. CHANG

- I. Introduction 241
- II. Use of Gene-Modified Tumors to Generate Antitumor-Reactive T Cells 242
- III. Genetic Manipulation of T Cells to Enhance Antitumor Reactivity 246
- IV. Genetic Modulation of Dendritic Cells 250
- V. Summary 251
- References 251

### 15. Update on the Use of Genetically Modified Hematopoietic Stem Cells for Cancer Therapy

EDSEL U. KIM, LEE G. WILKE, AND JAMES J. MULÉ

- I. Introduction 257
- II. Human Hematopoietic Stem Cells as Vehicles of Gene Transfer 258
- III. Preclinical Studies of Gene Transfer into Hematopoietic Stem Cells 259



- IV. Applications of Genetically Manipulated Hematopoietic Stem Cells to the Therapy of Human Cancer 262
- V. Conclusions 268
- References 268

---

P A R T

**III**

**ONCOGENE-TARGETED  
GENE THERAPY**

**16. Clinical Applications of  
Tumor-Suppressor Gene Therapy**

RAYMOND D. MENG AND WAFIK S. EL-DEIRY

- I. Introduction 273
- II. p53 273
- III. *BRCA1* 275
- IV. Onyx-015 Adenoviruses 275
- V. Summary and Future Work 276
- References 277

**17. Cancer Gene Therapy with Tumor  
Suppressor Genes Involved  
in Cell-Cycle Control**

RAYMOND D. MENG AND WAFIK S. EL-DEIRY

- I. Introduction 279
- II. p21<sup>WAF1/CIP1</sup> 280
- III. p16<sup>INK4</sup> 284
- IV. *Rb* 285
- V. p14<sup>ARF</sup> 286
- VI. p27<sup>Kip1</sup> 286
- VII. E2F-1 287
- VIII. *PTEN* 288
- IX. *BRCA1* 288
- X. *VHL* 289
- XI. *FHIT* 289
- XII. Apoptosis-Inducing Genes 289
- XIII. Conclusions 291
- References 291

**18. Cancer Gene Therapy with the p53  
Tumor Suppressor Gene**

RAYMOND D. MENG AND WAFIK S. EL-DEIRY

- I. Introduction 299
- II. Vectors for Gene Therapy 300

- III. p53 302
- IV. Conclusions 308
- References 308

**19. Antisense Downregulation of the  
Apoptosis-Related Bcl-2 and Bcl-xl  
Proteins: A New Approach  
to Cancer Therapy**

IRINA V. LEBEDEVA AND C.A. STEIN

- I. The Bcl Family of Proteins and their Role in Apoptosis 315
- II. Downregulation of Bcl-2 Expression: Antisense Strategies 316
- References 324

**20. Gene Therapy for Chronic  
Myelogenous Leukemia**

CATHERINE M. VERFAILLIE AND  
ROBERT CH ZHAO

- I. Molecular Mechanisms Underlying Ph<sup>+</sup> Leukemias 331
- II. Therapy 331
- III. Gene-Disruption Methods 332
- IV. Anti-*bcr-abl* Targeted Therapies 332
- V. Anti-*bcr-abl* Drug-Resistance Gene Therapy for CML 332
- VI. Conclusion 334
- References 334

---

P A R T

**IV**

**MANIPULATION OF DRUG  
RESISTANCE MECHANISMS BY  
GENE THERAPY**

**21. Transfer of Drug-Resistance Genes into  
Hematopoietic Progenitors**

OMER N. KOÇ, STEVEN P. ZIELSKE,  
JUSTIN C. ROTH, JANE S. REESE, AND  
STANTON L. GERSON

- I. Introduction 341
- II. Rationale for Drug-Resistance Gene Therapy 342

- III. Methyltransferase-Mediated Drug Resistance 344
- IV. Cytidine Deaminase 348
- V. Glutathione-S-Transferase 348
- VI. Dual-Drug-Resistance Approach 349
- VII. Clinical Trials 350
- VIII. Conclusion 351
- References 351

## 22. Multidrug-Resistance Gene Therapy in Hematopoietic Cell Transplantation

RAFAT ABONOUR, JAMES M. CROOP,  
AND KENNETH CORNETTA

- I. Introduction 355
- II. P-Glycoprotein 356
- III. Targeting Hematopoietic Progenitor Cells for Genetic Modification 356
- IV. Expression of P-Glycoprotein in Murine Hematopoietic Progenitors 357
- V. Expression of P-Glycoprotein in Human Hematopoietic Progenitors 358
- VI. Results of Early Phase I Studies Using MDR1-Transduced Hematopoietic Cells 359
- VII. Overcoming Transduction Inefficiency 360
- VIII. MDR1 Gene Transfer into Humans: Recent Progress 361
- IX. Implication and Future of MDR1 Gene Therapy in Humans 361
- References 362

## 23. Development and Application of an Engineered Dihydrofolate Reductase and Cytidine-Deaminase-Based Fusion Genes in Myeloprotection-Based Gene Therapy Strategies

OWEN A. O'CONNOR, TULIN BUDAK-ALPDOGAN, AND  
JOSEPH R. BERTINO

- I. Introduction 365
- II. Fusion Genes 368
- III. Development of Clinically Applicable Gene Transfer Approaches 370
- IV. Preclinical Evidence for Myeloprotection Strategies 371
- V. Clinical Applications of Myeloprotection Strategies 373
- VI. Challenges 377
- References 378

## 24. Protection from Antifolate Toxicity by Expression of Drug-Resistant Dihydrofolate Reductase

R. SCOTT McIVOR

- I. Introduction 383
- II. Drug-Resistant Dihydrofolate Reductases 384
- III. Protection from Antifolate Toxicity *In Vitro* 385
- IV. Protection from Antifolate Toxicity *In Vivo*: Retroviral Transduction Studies 386
- V. Dihydrofolate Reductase Transgenic Mouse System for *In Vivo* Drug-Resistance Studies 386
- VI. Antitumor Studies in Animals Expressing Drug-Resistant Dihydrofolate Reductase 387
- VII. Antifolate-Mediated *In Vivo* Selection of Hematopoietic Cells Expressing Drug-Resistant Dihydrofolate Reductase 388
- VIII. Summary and Future Considerations 388
- References 389

## 25. A Genomic Approach to the Treatment of Breast Cancer

K.V. CHIN, DEBORAH TOPPMAYER, THOMAS KEARNEY,  
MICHAEL REISS, EDMUND C. LATTIME, AND WILLIAM N. HAIT

- I. Introduction 393
- II. Toward a Genomic Approach to Therapy 393
- III. The Use of DNA Microarrays to Understand Drug Resistance 396
- IV. Effects of Genomic-Based Approaches on the Management of Breast Cancer Patients 398
- References 399

## PART

## V

## ANTI-ANIOGENESIS AND PRO-APOPTOTIC GENE THERAPY

## 26. Antiangiogenic Gene Therapy

STEVEN K. LIBUTTI AND ANDREW L. FELDMAN

- I. Introduction 405
- II. Angiogenesis and its Role in Tumor Biology 405
- III. Antiangiogenic Therapy of Cancer and the Role of Gene Therapy 406
- IV. Preclinical Models of Antiangiogenic Gene Therapy 407

- V. Inhibiting Proangiogenic Cytokines 412
- VI. Endothelial Cell-Specific Gene Delivery 414
- VII. Future Directions in Antiangiogenic Gene Therapy 415
- References 415

## 27. VEGF-Targeted Antiangiogenic Gene Therapy

CALVIN J. KUO, FILIP A. FARNEBO, CHRISTIAN M. BECKER,  
AND JUDAH FOLKMAN

- I. Introduction 421
- II. Angiogenesis and Tumor Growth 422
- III. Gene Therapy for Delivery of Antiangiogenic Factors 422
- IV. Antiangiogenic Gene Therapy in the Experimental and Clinical Settings 423
- V. Vascular Endothelial Growth Factor and Receptors 423
- VI. Vascular Endothelial Growth Factor and Angiogenesis 424
- VII. Vascular Endothelial Growth Factor Inhibition by Gene Transfer 425
- VIII. Issues Regarding Clinical Translation of Antiangiogenic Gene Therapy 428
- IX. Conclusion 432
- References 432

## 28. Strategies for Combining Gene Therapy with Ionizing Radiation to Improve Antitumor Efficacy

DAVID H. GORSKI, HELENA J. MAUCERI,  
AND RALPH R. WEICHELBAUM

- I. Introduction 435
- II. Strategies Using Gene Therapy to Increase the Efficacy of Radiation Therapy 436
- III. Enhancing the Replicative Potential of Antitumor Viruses with Ionizing Radiation 440
- IV. Transcriptional Targeting of Gene Therapy with Ionizing Radiation (Genetic Radiotherapy) 441
- V. Summary and Future Directions 443
- References 444

## 29. Virotherapy with Replication-Selective Oncolytic Adenoviruses: A Novel Therapeutic Platform for Cancer

DAVID KIRN

- I. Introduction 449
- II. Attributes of Replication-Selective Adenoviruses for Cancer Treatment 451

- III. Biology of Human Adenovirus 451
- IV. Mechanisms of Adenovirus-Mediated Cell Killing 451
- V. Approaches to Optimizing Tumor-Selective Adenovirus Replication 452
- VI. Background: *dl1520* (ONYX-015) 452
- VII. Clinical Trial Results with Wild-Type Adenovirus: Flawed Study Design 453
- VIII. A Novel Staged Approach to Clinical Research with Replication-Selective Viruses: *dl1520* (ONYX-015) 454
- IX. Results from Clinical Trials with *dl1520* (ONYX-015) 455
- X. Results from Clinical Trials with *dl1520* (ONYX-015): Summary 459
- XI. Future Directions 460
- XII. Summary 462
- References 462

## 30. E1A Cancer Gene Therapy

DUEN-HWA YAN, RUPING SHAO, AND MIEN-CHIE HUNG

- I. Introduction 465
- II. HER2 Overexpression and E1A-Mediated Antitumor Activity 465
- III. Mechanisms of E1A-Mediated Anti-Tumor Activity 467
- IV. E1A Gene Therapy: Preclinical Models 470
- V. E1A Gene Therapy: Clinical Trials 472
- VI. Conclusion 473
- References 473

## PART

## VI

## PRODRUG ACTIVATION STRATEGIES FOR GENE THERAPY OF CANCER

### 31. Preemptive and Therapeutic Uses of Suicide Genes for Cancer and Leukemia

FREDERICK L. MOOLTEN AND PAULA J. MROZ

- I. Introduction 481
- II. Therapeutic Uses of Suicide Genes 482
- III. Preemptive Uses of Suicide Genes in Cancer 483
- IV. Creation of Stable Suicide Functions by Combining Suicide Gene Transduction with Endogenous Gene Loss 485
- V. Preemptive Uses of Suicide Genes to Control Graft-Versus-Host Disease in Leukemia 487

VI. Future Prospects for Preemptive Use of Suicide Genes	488
References	489

### **32. Treatment of Mesothelioma Using Adenoviral-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Gene in Combination with Ganciclovir**

DANIEL H. STERMAN AND STEVEN M. ALBELDA

I. Introduction	493
II. Clinical Use of HSV-TK in the Treatment of Localized Malignancies	494
III. Challenges and Future Directions	499
References	501

### **33. The Use of Suicide Gene Therapy for the Treatment of Malignancies of the Brain**

KEVIN D. JUDY AND STEPHEN L. ECK

I. Introduction	505
II. Retrovirus Vector for HSV-TK	506
III. Adenovirus Vector for HSV-TK	509
IV. Herpes Simplex Virus Vectors Expressing Endogenous HSV-TK	510

V. Promising Preclinical Studies	510
References	511

### **34. Case Study of Combined Gene and Radiation Therapy as an Approach in the Treatment of Cancer**

BIN S. TEH, MARIA T. VLACHAKI, LAURA K. AGUILAR, BRIAN MILES, GUSTAVO AYALA, DOV KADMON, THOMAS WHEELER, TIMOTHY C. THOMPSON, E. BRIAN BUTLER, AND ESTUARDO AGUILAR-CORDOVA

I. Introduction	513
II. Background of the Field	514
III. Recent Advances in Herpes Simplex Virus-Thymidine Kinase Suicide Gene Therapy	515
IV. Combined Herpes Simplex Virus-Thymidine Kinase Suicide Gene Therapy and Radiotherapy	516
V. Issues Regarding Clinical Trials, Translation into Clinical Use, Preclinical Development, Efficacy, Endpoints, and Gene Expression	521
VI. Potential Novel Uses and Future Directions	522
References	523

Index	525
-------	-----



P A R T I

---

# VECTORS FOR GENE THERAPY OF CANCER